Girl’s undisclosed death in gene-editing trial raises red flags in booming Chinese industry

A top Chinese medical university is under scrutiny following the death of a young girl during an experimental gene-editing trial, raising alarm over ethical lapses in the nation's fast-growing biomedical sector. The incident, involving a clinical trial conducted at Shanghai Jiaotong University School of Medicine-affiliated Xinhua Hospital, has sparked renewed debate about the oversight and transparency of genetic interventions in China. The girl, whose identity has not been disclosed, died as a result of the trial, according to the university’s statement. It confirmed that a working group has been formed to investigate the case and the associated scientific paper. The probe comes amid growing international attention on the ethical boundaries of gene-editing practices, particularly in light of past controversies within the field. The trial, which took place last year, was partially funded by the girl’s parents, who reportedly spent $860,000 on the treatment. They claimed they were not informed of the potential risks, including the possibility of fatality, and had sought a cure for a genetic condition linked to developmental delays. According to reports from Science magazine and Retraction Watch, the hospital’s ethics board acknowledged a direct link between the treatment and the girl’s death. However, the response from the institution was deemed insufficient, with no official disclosure of the outcome to the family or the broader public. This case has intensified public concern in China, especially after the 2018 scandal involving He Jiankui, a scientist who edited the genomes of human embryos, an act widely condemned as unethical. While He’s actions were met with legal consequences, the current situation involves established researchers at a prestigious academic institution, drawing further criticism. Gene therapy, which encompasses gene-editing techniques, is increasingly central to China’s biotech ambitions. Researchers are competing globally for advancements in treating genetic disorders, often leveraging the country’s flexible regulatory framework. This system permits “investigator-initiated trials,” allowing smaller studies to proceed with less stringent oversight compared to conventional drug approvals. Such trials can accelerate access to new treatments, particularly for rare conditions, but critics argue they lack sufficient safeguards. Experts have pointed to systemic issues in the oversight of such trials. Joy Zhang, a scholar at the University of Kent, noted that while the He Jiankui case was unprecedented, the current incident reflects ongoing challenges in ensuring ethical compliance. She emphasized that the presence of high-profile researchers does not guarantee adherence to best practices, highlighting the need for stronger institutional accountability. Yanzhong Huang, a senior fellow at the Council on Foreign Relations, echoed similar concerns. He described the case as emblematic of deeper flaws in regulatory frameworks, suggesting that the incident might represent just the beginning of a larger pattern. Huang highlighted the absence of transparency, safety measures, and clear accountability mechanisms, all of which contribute to the risk of ethical breaches. As the investigation unfolds, the broader implications for China’s biotech industry remain uncertain. With gene therapy becoming a key growth area, the balance between innovation and ethical responsibility will continue to be scrutinized. The case underscores the urgent need for improved governance and greater public awareness of the risks and responsibilities inherent in cutting-edge medical research.